secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2022-10-03T23:59:59+00:00
Accession:  0001867096-22-000111
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma enters amended lease for 87,032 sq ft Chicago HQ; base rent $52.50/sq ft
--------------------------------------------------------------------------------

- Xeris Pharma leases 87,032 sq ft office/lab at 1375 W. Fulton, Chicago; term through 2037.
- Annual base rent $52.50/sq ft in year one, escalating 2.5% annually; rent abatement for first 12 months.
- Letter of credit increased from $408,263 to $3,247,808 to secure lease obligations.
- Company to relocate HQ to premises in H1 2023; current HQ at 180 N. LaSalle to be subleased.
- Credit agreement amended to permit issuance of the letter of credit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000111/0001867096-22-000111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709622000111/xers-20220929.htm
  HTML page:      https://secwatch.observer/filing/0001867096-22-000111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer